Table 2 Visit and assessment schedule in the MRCSDH trial
Activities | Screening or baseline | Pre-treatment | At discharge | 3 M ± 7D | 6 M ± 7D | 12M ± 7D | 24 ± 7D |
|---|---|---|---|---|---|---|---|
Informed consent | ✓ | ||||||
Inclusion/exclusion criteria | ✓ | ||||||
General information | ✓ | ||||||
Medical history | ✓ | ||||||
Medication history | ✓ | ||||||
Personal history | ✓ | ||||||
Physical examination | ✓ | ✓ | |||||
Vital sign | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
Neurological symptoms | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
Hematoma volume by CT/MRI | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Lab test | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
Pregnancy test | ✓ | ||||||
Electrocardiogram | ✓ | ||||||
Treatment strategy | ✓ | ✓ | |||||
Current medication | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
mRS assessment | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
GCS | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
Adverse events | ✓ | ✓ | ✓ | ✓ | ✓ | ||
Recurrence | ✓ | ✓ | ✓ | ✓ | ✓ |